Prosensa Holding B.V. developed therapeutics on the basis of RNA modulation, thereby intervening in an intermediate step in protein biosynthesis.
The company’s lead program was in Duchenne Muscular Dystrophy (DMD), a genetic disorder that blocks the synthesis of an important protein. DMD leads to progressive paralysis and eventually to death.
Portfolio: MedSciences Capital B.V. and MedSciences Capital II B.V.
Current stage: Acquired by Biomarin.
